Literature DB >> 18277917

Completion of therapy for latent tuberculosis in children of different nationalities.

Dwight A Powell1, Lori Perkins, Shu-Hua Wang, Garrett Hunt, Nancy Ryan-Wenger.   

Abstract

We performed a retrospective review of prospectively stored data on 545 children from 54 different birth countries with latent tuberculosis cared for in a pediatric tuberculosis clinic between August 1, 2005 and July 31, 2006. For analysis, patients were grouped into 6 geographic regions. The overall rate of completion of therapy was 54.4%. There were no significant differences among regions in the rate of completion of therapy by age, duration in the United States, or exposure to active tuberculosis. However, no children from Eastern Europe completed therapy compared with 67.9% from Central and South America. Of those children who did not complete therapy, parental refusal to start medication accounted for 54% and 80% of Eastern European and Asian children compared with <10% of children from Sub-Saharan Africa, Central and South America, and the United States.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18277917     DOI: 10.1097/INF.0b013e3181609a0a

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  4 in total

Review 1.  Old and new approaches to diagnosing and treating latent tuberculosis in children in low-incidence countries.

Authors:  Andrea T Cruz; Jeffrey R Starke; Mark N Lobato
Journal:  Curr Opin Pediatr       Date:  2014-02       Impact factor: 2.856

Review 2.  A scoping review of paediatric latent tuberculosis infection care cascades: initial steps are lacking.

Authors:  Jeffrey I Campbell; Thomas J Sandora; Jessica E Haberer
Journal:  BMJ Glob Health       Date:  2021-05

3.  Four months of rifampicin monotherapy for latent tuberculosis infection in children.

Authors:  Chi Eun Oh; Dick Menzies
Journal:  Clin Exp Pediatr       Date:  2021-10-29

4.  Window Period Prophylaxis for Children Exposed to Tuberculosis, Houston, Texas, USA, 2007-2017.

Authors:  Andrea T Cruz; Jeffrey R Starke
Journal:  Emerg Infect Dis       Date:  2019-03       Impact factor: 6.883

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.